Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS

被引:5
作者
Rahmel, Tim [1 ]
Asmussen, Sven [1 ]
Karlik, Jan [2 ,3 ]
Steinmann, Joerg [4 ]
Adamzik, Michael [1 ,2 ,3 ]
Peters, Juergen [2 ,3 ]
机构
[1] Univ Klinikum Knappschaftskrankenhaus Bochum, Klin Anasthesiol Intens Med & Schmerztherapie, Schornau 23-25, D-44892 Bochum, Germany
[2] Univ Duisburg Essen, Klin Anasthesiol & Intens Med, D-45122 Essen, Germany
[3] Univ Klinikum Essen, D-45122 Essen, Germany
[4] Univ Klinikum Essen, Inst Med Mikrobiol, D-45147 Essen, Germany
来源
BMC ANESTHESIOLOGY | 2017年 / 17卷
关键词
Acute respiratory distress syndrome; CAP; 30-day mortality; Liver failure; S3; guideline; Consensus guideline; ACUTE LUNG INJURY; RANDOMIZED CONTROLLED-TRIALS; INTENSIVE-CARE UNITS; INFECTIOUS-DISEASES; CLINICAL-TRIAL; FLUOROQUINOLONES; MANAGEMENT; MORTALITY; EPIDEMIOLOGY; METAANALYSIS;
D O I
10.1186/s12871-017-0376-5
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: We tested the hypothesis that moxifloxacin monotherapy is equally effective and safe as a betalactam antibiotic based combination therapy in patients with acute respiratory distress syndrome (ARDS) evoked by severe community acquired pneumonia (CAP). Methods: In a retrospective chart review study of 229 patients with adult respiratory distress syndrome (ARDS) admitted to our intensive care unit between 2001 and 2011, 169 well-characterized patients were identified to suffer from severe CAP. Patients were treated with moxifloxacin alone, moxifloxacin in combination with beta-lactam antibiotics, or with another antibiotic regimen based on beta-lactam antibiotics, at the discretion of the admitting attending physician. The primary endpoint was 30-day survival. To assess potential drug-induced liver injury, we also analyzed biomarkers of liver cell integrity. Results: 30-day survival (69% overall) did not differ (p = 0.89) between moxifloxacin monotherapy (n = 42), moxifloxacin combination therapy (n = 44), and other antibiotic treatments (n = 83). We found significantly greater maximum activity of aspartate transaminase (p = 0.048), alanine aminotransferase (p = 0.003), and direct bilirubin concentration (p = 0.01) in the moxifloxacin treated groups over the first 10-20 days. However, these in-between group differences faded over time, and no differences remained during the last 10 days of observation. Conclusions: In CAP evoked ARDS, moxifloxacin monotherapy and moxifloxacin combination therapy was not different to a betalactam based antibiotic regimen with respect to 30-day mortality, and temporarily increased markers of liver cell integrity had no apparent clinical impact. Thus, in contrast to the current S3 guidelines, moxifloxacin may also be safe and effective even in patients with severe CAP evoked ARDS while providing coverage of an extended spectrum of severe CAP evoking bacteria. However, further prospective studies are needed for definite recommendations.
引用
收藏
页数:9
相关论文
共 28 条
  • [1] Fluoroquinolones in the management of community-acquired pneumonia
    Albertson, T. E.
    Dean, N. C.
    El Solh, A. A.
    Gotfried, M. H.
    Kaplan, C.
    Niederman, M. S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (03) : 378 - 388
  • [2] Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia
    Baddour, LM
    Yu, VL
    Klugman, KP
    Feldman, C
    Ortqvist, A
    Rello, J
    Morris, AJ
    Luna, CM
    Snydman, DR
    Ko, WC
    Chedid, MBF
    Hui, DS
    Andremont, A
    Chiou, CCC
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (04) : 440 - 444
  • [3] The standard of care of patients with ARDS: ventilatory settings and rescue therapies for refractory hypoxemia
    Bein, Thomas
    Grasso, Salvatore
    Moerer, Onnen
    Quintel, Michael
    Guerin, Claude
    Deja, Maria
    Brondani, Anita
    Mehta, Sangeeta
    [J]. INTENSIVE CARE MEDICINE, 2016, 42 (05) : 699 - 711
  • [4] Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries
    Bellani, Giacomo
    Laffey, John G.
    Pham, Tai
    Fan, Eddy
    Brochard, Laurent
    Esteban, Andres
    Gattinoni, Luciano
    van Haren, Frank
    Larsson, Anders
    McAuley, Daniel F.
    Ranieri, Marco
    Rubenfeld, Gordon
    Thompson, B. Taylor
    Wrigge, Hermann
    Slutsky, Arthur S.
    Pesenti, Antonio
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (08): : 788 - 800
  • [5] REPORT OF THE AMERICAN-EUROPEAN CONSENSUS CONFERENCE ON ARDS - DEFINITIONS, MECHANISMS, RELEVANT OUTCOMES AND CLINICAL-TRIAL COORDINATION
    BERNARD, GR
    ARTIGAS, A
    BRIGHAM, KL
    CARLET, J
    FALKE, K
    HUDSON, L
    LAMY, M
    LEGALL, JR
    MORRIS, A
    SPRAGG, R
    DHAINAUT, JF
    MATTHAY, M
    MANCEBO, J
    MEYRICK, B
    PAYEN, D
    PERRET, C
    FOWLER, AA
    SCHALLER, MD
    VANASBECK, BS
    COCHIN, B
    LANKEN, PN
    LEEPER, KV
    MARINI, J
    MURRAY, JF
    OPPENHEIMER, L
    PESENTI, A
    REID, L
    RINALDO, J
    VILLAR, J
    Hyers, T
    Knaus, W
    Matthay, R
    Pinsky, M
    Bone, RC
    Bosken, C
    Johanson, WG
    Lewandowski, K
    Repine, J
    Rodriguez-Roisin, R
    Roussos, C
    [J]. INTENSIVE CARE MEDICINE, 1994, 20 (03) : 225 - 232
  • [6] ARDS - an update
    Braune, S.
    Kluge, S.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (19) : 1019 - 1022
  • [7] Epidemiology and outcome of acute lung injury in European intensive care units - Results from the ALIVE study
    Brun-Buisson, C
    Minelli, C
    Bertolini, G
    Brazzi, L
    Pimentel, J
    Lewandowski, K
    Bion, J
    Rornand, JA
    Villar, J
    Thorsteinsson, A
    Damas, P
    Armaganidis, A
    Lemaire, FO
    [J]. INTENSIVE CARE MEDICINE, 2004, 30 (01) : 51 - 61
  • [8] 10 years' experience with the pneumococcal quinolone moxifloxacin
    Burkhardt, Olaf
    Welte, Tobias
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (06) : 645 - 668
  • [9] IDENTIFICATION OF PATIENTS WITH ACUTE LUNG INJURY - PREDICTORS OF MORTALITY
    DOYLE, RL
    SZAFLARSKI, N
    MODIN, GW
    WIENERKRONISH, JP
    MATTHAY, MA
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (06) : 1818 - 1824
  • [10] Management of Adult Community-acquired Pneumonia and Prevention - Update 2016 Guideline of the German Respiratory Society, the Paul-Ehrlich-Society for Chemotherapy, the German Society for Infectious Diseases, the Competence Network CAPNETZ, the Austrian Respiratory Society, the Austrian Society for Infectious and Tropical Diseases and the Swiss Respiratory Society
    Ewig, S.
    Hoeffken, G.
    Kern, W. V.
    Rohde, G.
    Flick, H.
    Krause, R.
    Ott, S.
    Bauer, T.
    Dalhoff, K.
    Gatermann, S.
    Kolditz, M.
    Krueger, S.
    Lorenz, J.
    Pletz, M.
    de Roux, A.
    Schaaf, B.
    Schaberg, T.
    Schuette, H.
    Welte, T.
    [J]. PNEUMOLOGIE, 2016, 70 (03): : 151 - 200